Cargando…
Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
BACKGROUND: There is paucity of data using direct anti-viral agents (DAA) in patients on maintenance hemodialysis (MHD) infected with HCV-genotype 1 & 3. Aim of the study was to evaluate DAA therapy in patients infected with HCV-genotype 1 & 3 on MHD. METHODS: A prospective open label, paral...
Autores principales: | Cheema, Shafiq Ur Rehman, Rehman, Muhammad Salman, Hussain, Ghulam, Cheema, Sidra Shafiq, Gilani, Nooman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883698/ https://www.ncbi.nlm.nih.gov/pubmed/31779583 http://dx.doi.org/10.1186/s12882-019-1631-4 |
Ejemplares similares
-
Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019) -
Immunoglobulin A nephropathy associated with acute hepatitis E infection: First case report
por: Cheema, Sidra Shafiq, et al.
Publicado: (2023) -
Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016) -
Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
por: Sperl, Jan, et al.
Publicado: (2017) -
Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)